HRP20230308T1 - Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina - Google Patents
Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina Download PDFInfo
- Publication number
- HRP20230308T1 HRP20230308T1 HRP20230308TT HRP20230308T HRP20230308T1 HR P20230308 T1 HRP20230308 T1 HR P20230308T1 HR P20230308T T HRP20230308T T HR P20230308TT HR P20230308 T HRP20230308 T HR P20230308T HR P20230308 T1 HRP20230308 T1 HR P20230308T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- human individual
- antibody
- antigen
- Prior art date
Links
- 108010056852 Myostatin Proteins 0.000 title claims 10
- 208000030159 metabolic disease Diseases 0.000 title claims 7
- 230000004913 activation Effects 0.000 title claims 2
- 102000004472 Myostatin Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 210000003205 muscle Anatomy 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 6
- 208000016097 disease of metabolism Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 5
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 108010059616 Activins Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 2
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 239000000488 activin Substances 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 210000003486 adipose tissue brown Anatomy 0.000 claims 2
- 210000000593 adipose tissue white Anatomy 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102000008934 Muscle Proteins Human genes 0.000 claims 1
- 108010074084 Muscle Proteins Proteins 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 235000019577 caloric intake Nutrition 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Claims (19)
1. Pripravak koji sadrži inhibitor miostatina gdje on predstavlja protutijelo ili njegov fragment koji veže antigen, naznačen time, da je za uporabu kao lijek u liječenju metaboličke bolesti kod ljudskog pojedinca, pri čemu postupak obuhvaća sljedeće korake:
odabir ljudskog pojedinca koji boluje od metaboličke bolesti; i
primjena na ljudskom pojedincu pripravka koji sadrži učinkovitu količinu protutijela, ili njegovog fragmenta koji veže antigen;
pri čemu metabolička bolest je pretilost, metabolički sindrom, nealkoholni steatohepatitis (NASH), nealkoholna bolest masne jetre (NAFDL) i/ili dijabetes;
dok je ljudski pojedinac na dijeti sa smanjenim unosom kalorija.
2. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da se protutijelo ili njegov fragment koji veže antigen specifično veže na pro/latentni miostatin.
3. Pripravak za uporabu prema patentnom zahtjevu 2, naznačen time, da se protutijelo ili njegov fragment koji veže antigen specifično veže na pro/latentni miostatin i blokira aktivaciju zrelog miostatina.
4. Pripravak za uporabu prema patentnom zahtjevu 2 ili 3, naznačen time, da se protutijelo ili njegov fragment koji veže antigen specifično veže na pro/latentni miostatin i blokira oslobađanje zrelog miostatina.
5. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da protutijelo ili njegov fragment veže zreli miostatin.
6. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, da metabolička bolest je pretilost.
7. Pripravak za uporabu prema patentnom zahtjevu 6, naznačen time, da pretilost je pretilost koja je inducirana prehranom.
8. Pripravak za uporabu prema patentnom zahtjevu 6 ili 7, naznačen time, da pretilost je sarkopenijska pretilost.
9. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, da metabolička bolest je dijabetes.
10. Pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da dijabetes je dijabetes tipa II.
11. Pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da dijabetes je dijabetes tipa I.
12. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, da metabolička bolest je NASH.
13. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, da primjena pripravka uzrokuje najmanje jedno od sljedećih:
a) povećanje mase i/ili funkcije mišićnog tkiva kod ljudskog pojedinca;
b) povećanje mase i/ili funkcije mišićnog tkiva brze kontrakcije kod ljudskog pojedinca;
c) povećanje mase i/ili funkcije mišićnog tkiva spore kontrakcije kod ljudskog pojedinca;
d) povećanje brzine metabolizma kod ljudskog pojedinca;
e) povećanje inzulinske osjetljivosti kod ljudskog pojedinca;
f) povećanje razine smeđeg masnog tkiva kod ljudskog pojedinca;
g) povećanje razine bež masnog tkiva kod ljudskog pojedinca;
h) smanjenje razine bijelog masnog tkiva kod ljudskog pojedinca;
i) smanjenje razine visceralnog masnog tkiva kod ljudskog pojedinca;
j) smanjenje omjera masnog tkiva prema mišićnom tkivu kod ljudskog pojedinca;
k) povećanje nakupljanja glukoze putem ciljanog tkiva kod ljudskog pojedinca, pri čemu se ciljano tkivo bira iz skupine koju čine smeđe masno tkivo, bež masno tkivo, i mišićno tkivo;
l) smanjenje nakupljanja glukoze putem ciljanog tkiva kod ljudskog pojedinca, pri čemu se ciljano tkivo bira iz skupine koju čine bijelo masno tkivo, i tkivo jetre;
m) smanjenje mišićnog katabolizma proteina i/ili mišićnog otpuštanja aminokiselina kod ljudskog pojedinca;
n) povećanje glikemijske kontrole ovisne o inzulinu kod ljudskog pojedinca;
o) smanjenje unutarmišićne infiltracije masnoće kod ljudskog pojedinca;
p) poboljšanje standardiziranih testnih rezultata kvalitete života;
q) sprečavanje gubitka mišića ili mišićne atrofije kod ljudskog pojedinca;
r) povećanje gustoće kostiju ili volumen;
s) sprečavanje ili smanjenje gubitka kostiju ili frakture;
t) smanjenje preopterećenja fluidom ili edema koji je povezan s kroničnim srčanim zastojem (CHF); i/ili
u) pospješivanje učinkovite osjetljivosti pojedinca na liječenje.
14. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-13, naznačen time, da se protutijelo, ili njegov fragment koji veže antigen, ne veže na GDF11 ili Aktivin, opcionalno gdje se protutijelo, ili njegov fragment koji veže antigen, ne veže na zreli miostatin, GDF11 ili Aktivin.
15. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-14, naznačen time, da protutijelo, ili njegov fragment koji veže antigen sadrži regiju koja određuje komplementarnost (CDR) H1 kao što je u SEQ ID NO: 1 ili 2, CDR H2 u skladu sa SEQ ID NO: 4 ili 5, CDR H3 u skladu sa SEQ ID NO: 10, CDR L1 u skladu sa SEQ ID NO: 12 ili 13, CDR L2 u skladu sa SEQ ID NO: 18 ili 19, i CDR L3 u skladu sa SEQ ID NO: 22.
16. Pripravak za uporabu prema patentnom zahtjevu 15, naznačen time, da protutijelo, ili njegov fragment koji veže antigen, sadrži:
a) varijabilnu regiju teškog lanca koja ima aminokiselinski slijed SEQ ID NO: 25 i varijabilnu regiju lakog lanca koja ima aminokiselinski slijed SEQ ID NO: 31; ili
b) teški lanac koji sadrži aminokiselinski slijed SEQ ID NO: 50 i laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 51.
17. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-16, naznačen time, da se protutijelo, ili njegov fragment koji veže antigen, natječe za vezanje na pro/latentni miostatin s protutijelom, ili njegovim fragmentom koji veže antigen iz patentnog zahtjeva 16.
18. Pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se afinitet protutijela, ili njegovog fragmenta koji veže antigen za FcRn, povećava kako bi se proširila njegova farmakokinetička svojstva; opcionalno pri čemu se protutijelo, ili njegov fragment koji veže antigen konstruira inženjeringom kako bi vezao FcRn s većim afinitetom uz pH 7,4.
19. Pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se pripravak primjenjuje supkutano.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443455P | 2017-01-06 | 2017-01-06 | |
| EP17150586 | 2017-01-06 | ||
| US201762530311P | 2017-07-10 | 2017-07-10 | |
| US201762608069P | 2017-12-20 | 2017-12-20 | |
| EP18701237.2A EP3565592B1 (en) | 2017-01-06 | 2018-01-05 | Treating metabolic diseases by inhibiting myostatin activation |
| PCT/US2018/012686 WO2018129395A1 (en) | 2017-01-06 | 2018-01-05 | Methods for treating metabolic diseases by inhibiting myostatin activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230308T1 true HRP20230308T1 (hr) | 2023-05-12 |
Family
ID=61022453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230308TT HRP20230308T1 (hr) | 2017-01-06 | 2018-01-05 | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11155611B2 (hr) |
| EP (2) | EP4218817A3 (hr) |
| JP (2) | JP7198757B2 (hr) |
| AU (2) | AU2018205270B2 (hr) |
| CA (1) | CA3088855A1 (hr) |
| DK (1) | DK3565592T3 (hr) |
| ES (1) | ES2944357T3 (hr) |
| FI (1) | FI3565592T3 (hr) |
| HR (1) | HRP20230308T1 (hr) |
| HU (1) | HUE061656T2 (hr) |
| PL (1) | PL3565592T3 (hr) |
| RS (1) | RS64159B1 (hr) |
| SI (1) | SI3565592T1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| KR20230155021A (ko) | 2015-09-15 | 2023-11-09 | 스칼러 락, 인크. | 항-프로/잠재성-미오스타틴 항체 및 그의 용도 |
| AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| EP0690873B1 (en) | 1993-03-19 | 2003-06-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| JPH10502811A (ja) | 1994-07-08 | 1998-03-17 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−１１ |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| BR0107902A (pt) | 2000-01-28 | 2002-11-05 | Novo Nordisk As | Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade |
| KR101155294B1 (ko) | 2000-06-16 | 2013-03-07 | 캠브리지 안티바디 테크놀로지 리미티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| DE60128914T2 (de) | 2001-10-05 | 2008-05-08 | Affimed Therapeutics Ag | Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation |
| CN102764436A (zh) | 2002-07-19 | 2012-11-07 | 艾博特生物技术有限公司 | TNF α相关疾病的治疗 |
| JP4547561B2 (ja) | 2002-09-16 | 2010-09-22 | ザ ジョンズ ホプキンス ユニバーシティー | メタロプロテアーゼによるミオスタチンの活性化、およびミオスタチン活性の調節法 |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| RU2377253C2 (ru) | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
| AU2003301195B2 (en) * | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| US7371726B2 (en) | 2003-12-31 | 2008-05-13 | Schering-Plough Animal Health Corporation | Neutralizing GDF8 epitope-based growth enhancing vaccine |
| AU2005219441A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | ALK7 and myostatin inhibitors and uses thereof |
| CA2558805C (en) * | 2004-03-23 | 2011-09-27 | Eli Lilly And Company | Anti-myostatin antibodies |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7316998B2 (en) * | 2004-05-27 | 2008-01-08 | Acceleron Pharma Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| EP2361933A3 (en) | 2005-01-26 | 2012-05-02 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| KR20080011403A (ko) | 2005-04-25 | 2008-02-04 | 화이자 인크. | 미오스타틴에 대한 항체 |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| EA015589B1 (ru) | 2005-10-06 | 2011-10-31 | Эли Лилли Энд Компани | Антитела против миостатина и их применение |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| CA2693378C (en) * | 2006-08-03 | 2020-04-14 | Orico Limited | Myostatin antagonists |
| EP2066695B1 (en) * | 2006-09-05 | 2013-03-27 | Eli Lilly And Company | Anti-myostatin antibodies |
| EP2679237A1 (en) | 2006-11-29 | 2014-01-01 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| EP2124988B1 (en) | 2007-02-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| JP5670179B2 (ja) | 2007-03-30 | 2015-02-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 負の光学的分散を有する複屈折層 |
| CA2688563A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| BRPI1014522B8 (pt) | 2009-04-27 | 2021-05-25 | Novartis Ag | anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos |
| AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| US8945511B2 (en) * | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| CN102741276A (zh) * | 2009-10-01 | 2012-10-17 | 可维塔有限公司 | 合成的肌肉抑制素肽拮抗剂 |
| CN103003307B (zh) | 2010-03-10 | 2017-08-11 | 根马布股份公司 | 抗c‑MEt的单克隆抗体 |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| SG10201506405YA (en) | 2010-08-16 | 2015-10-29 | Amgen Inc | Polypeptides That Bind Myostatin, Compositions And Methods |
| JP6268097B2 (ja) | 2011-11-11 | 2018-01-24 | デューク・ユニヴァーシティ | 固形腫瘍治療のための併用薬物療法 |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| NZ702269A (en) | 2012-06-15 | 2017-07-28 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| JP2016500704A (ja) | 2012-11-06 | 2016-01-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 細胞シグナル伝達を変調するための組成物及び方法 |
| JP2016521283A (ja) | 2013-05-06 | 2016-07-21 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 成長因子モジュレーションのための組成物および方法 |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| EP3068407A1 (en) | 2013-11-11 | 2016-09-21 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016073906A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
| TWI808330B (zh) | 2014-12-19 | 2023-07-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
| CN107771081A (zh) | 2015-04-15 | 2018-03-06 | 瑞泽恩制药公司 | 用gdf8抑制剂增加力量和功能的方法 |
| KR20230155021A (ko) | 2015-09-15 | 2023-11-09 | 스칼러 락, 인크. | 항-프로/잠재성-미오스타틴 항체 및 그의 용도 |
| AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
-
2018
- 2018-01-05 PL PL18701237.2T patent/PL3565592T3/pl unknown
- 2018-01-05 FI FIEP18701237.2T patent/FI3565592T3/fi active
- 2018-01-05 JP JP2019536836A patent/JP7198757B2/ja active Active
- 2018-01-05 DK DK18701237.2T patent/DK3565592T3/da active
- 2018-01-05 ES ES18701237T patent/ES2944357T3/es active Active
- 2018-01-05 AU AU2018205270A patent/AU2018205270B2/en active Active
- 2018-01-05 HR HRP20230308TT patent/HRP20230308T1/hr unknown
- 2018-01-05 CA CA3088855A patent/CA3088855A1/en active Pending
- 2018-01-05 SI SI201830885T patent/SI3565592T1/sl unknown
- 2018-01-05 EP EP23158609.0A patent/EP4218817A3/en active Pending
- 2018-01-05 EP EP18701237.2A patent/EP3565592B1/en active Active
- 2018-01-05 RS RS20230295A patent/RS64159B1/sr unknown
- 2018-01-05 HU HUE18701237A patent/HUE061656T2/hu unknown
- 2018-01-05 US US16/474,330 patent/US11155611B2/en active Active
-
2021
- 2021-09-22 US US17/448,389 patent/US20220106390A1/en active Pending
-
2022
- 2022-11-02 JP JP2022175995A patent/JP2023012515A/ja active Pending
- 2022-11-08 AU AU2022268305A patent/AU2022268305A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018205270B2 (en) | 2022-08-11 |
| EP3565592A1 (en) | 2019-11-13 |
| US20190345239A1 (en) | 2019-11-14 |
| JP7198757B2 (ja) | 2023-01-04 |
| DK3565592T3 (da) | 2023-05-01 |
| FI3565592T3 (fi) | 2023-05-10 |
| EP4218817A2 (en) | 2023-08-02 |
| HUE061656T2 (hu) | 2023-07-28 |
| JP2023012515A (ja) | 2023-01-25 |
| US11155611B2 (en) | 2021-10-26 |
| US20220106390A1 (en) | 2022-04-07 |
| RS64159B1 (sr) | 2023-05-31 |
| SI3565592T1 (sl) | 2023-05-31 |
| EP3565592B1 (en) | 2023-03-01 |
| ES2944357T3 (es) | 2023-06-20 |
| CA3088855A1 (en) | 2018-07-12 |
| EP4218817A3 (en) | 2023-09-06 |
| AU2018205270A1 (en) | 2019-08-22 |
| PL3565592T3 (pl) | 2023-08-21 |
| JP2020514295A (ja) | 2020-05-21 |
| AU2022268305A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230308T1 (hr) | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina | |
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
| JP2019504064A5 (hr) | ||
| WO2012170438A3 (en) | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR | |
| JP6224608B2 (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| EP2386577A3 (en) | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof | |
| RU2015143242A (ru) | Антитела против gdf8 человека | |
| JP2019513751A5 (hr) | ||
| JP2018506277A5 (hr) | ||
| BRPI0415195A (pt) | anticorpos completamente humanos contra 4-1bb humana (cd137) | |
| JP2010512320A5 (hr) | ||
| DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
| RU2711478C2 (ru) | Композиции и способы борьбы с накоплением жировой ткани | |
| EP3670534A3 (en) | Human fgf receptor and beta-klotho binding proteins | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| MX2019005415A (es) | Anticuerpos de il-6 y uso de los mismos. | |
| EP2433650A3 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
| JP2015506944A5 (hr) | ||
| JP2016513664A5 (hr) | ||
| RU2016141919A (ru) | Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1) | |
| FI3553084T3 (fi) | Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa | |
| KR20220030306A (ko) | Anti-met 항체 및 그 용도 | |
| EA201891323A1 (ru) | Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1 | |
| RU2018139893A (ru) | Способ лечения или предупреждения болезней печени |